ZD6474(Vandetanib) + Alimta Combo Study
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Carcinoma; Non-Small Cell Lung; Lung Cancer
Intervention: ZD6474 (vandetanib) (Drug); pemetrexed (Drug)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Richard deBoer, MD, Principal Investigator, Affiliation: Western Hospital Footscray, Victoria, Australia
Peter Langmuir, Study Director, Affiliation: AstraZeneca
Summary
The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets)
to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help
control their symptoms and disease better than the chemotherapy alone.
Clinical Details
Official title: A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of Prior Chemotherapy.
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Primary outcome: To establish the safety & tolerability of ZD6474 when administered in combination w/Pemetrexed (Alimta) to patients w/locally advanced or metastatic NSCLC after failure of prior chemo, by assessment of AEs, vital signs, lab, ECG and physical exam.
Secondary outcome: To investigate the pharmacokinetics of ZD6474 and Pemetrexed when given in combination to patients with locally advanced or metastatic NSCLC after failure of prior chemotherapy, by assessment of appropriate pharmacokinetic (PK) parameters.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Confirmed advanced or metastatic non-small cell lung cancer
- Failure of first-line chemotherapy
- 1 or more measurable lesion by RECIST
Exclusion Criteria:
- Previous chemotherapy or radiotherapy within 4 weeks
- Significant cardiac events, arrythmias or other cardiac conditions
- Unacceptable laboratory measurements
Locations and Contacts
Additional Information
AstraZeneca Clinical Trial Information - Outside US
Starting date: July 2005
Ending date: March 2008
Last updated: June 12, 2008
|
